Gennex Laboratories share price
BSE: 531739Pharmaceuticals & BiotechnologySmall Cap
Last close ₹8.70down ₹0.15 (1.69%)
Share price at the BSE close on 23 Oct 2026. Previous close ₹8.85.
52-week range of traded prices to 23 Oct 2026
₹7.05Low, 30 Mar 2026₹17.25High, 28 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹211 Cr2,248th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 14 Aug 2026
- 11.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 0.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,30,459
Results
Standalone, as consolidated accounts are on record for only 9 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 14 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹35 Crdown 5.55%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹3.96 Crup 32.09%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 11.4%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2018, the company's revenue for that year, ₹44 Cr, differs from its quarters added, ₹47 Cr.
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 14 Feb | Mar 2025Filed 13 Jun | Jun 2025Filed 14 Aug | Sep 2025Filed 26 Nov | Dec 2025Filed 14 Feb | Mar 2026Filed 30 May | Jun 2026Filed 14 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.7 | 25.3 | 23.3 | 25.6 | 29.3 | 28.2 | 36.7 | 34.7 |
| Net profit | 4.2 | 4.2 | 1.5 | 4.1 | 4.5 | 4.5 | 3.0 | 4.0 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 16.8% | 16.7% | 6.5% | 16.2% | 15.5% | 15.8% | 8.2% | 11.4% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, "Bulk Drugs, Biotech Products and lntermediates", which carries all its revenue.
Valuation
Today, against the company's own history. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to earningsPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
At or below today's level on 1% of 923 trading days over the last 5 years.
LowestHighest
Its median22.0Industry median28.3
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 0.3% of 994 trading days over the last 5 years.
LowestHighest
Its median1.9Industry median2.9
EV to EBITDAEnterprise value to EBITDA. Market cap plus borrowings less cash and bank balances, divided by operating profit before depreciation (revenue less operating expenses, without other income and one-off items) over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly): what the whole business costs against the profit its operations make. Lease liabilities are not counted: the results filings do not state them.9.1
At or below today's level on 1% of 994 trading days over the last 5 years.
LowestHighest
Its median16.6Industry median18.7
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −40.8% | +8.1% | −45.2% | 0.0% |
| 3 years | +8.3% | +37.1% | −21.0% | 0.0% |
| 5 years | +12.8% | +16.0% | −2.8% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual funds holding it
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before.
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 4,816 | 0.01% | ₹48,000 |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 2,271 | 0.01% | ₹23,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Gennex Laboratories in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Ambalal Sarabhai EnterprisesAMBALALSA | 266 | 19.6 | 1.7 | 20.1 | +4.9% | +5.8% | 9.1% | 5.0% | 0.00% |
 Zenotech LaboratoriesZENOTECH | 246 | – | 2.6 | 61.1 | +4.6% | – | −2.6% | −3.9% | 0.00% |
 BDH IndustriesBDH | 244 | 20.8 | 3.2 | 14.2 | +44.8% | +22.9% | 16.1% | 18.2% | 1.18% |
 Everest OrganicsEVERESTO | 222 | 42.2 | 2.9 | 13.8 | +5.5% | −15.2% | 7.2% | 10.5% | 0.00% |
 Sat Kartar LifeSATKARTAR | 206 | 12.0 | 3.0 | – | – | – | 28.7% | – | 0.54% |
 Accretion PharmaceuticalsACCPL | 202 | 20.9 | 3.7 | – | +56.2% | +42.3% | 27.6% | – | 0.00% |
 Nectar LifesciencesNECLIFE | 200 | – | 0.3 | – | −99.7% | – | −31.9% | −15.4% | 0.00% |
 Accretion NutravedaANL | 198 | 39.0 | 5.6 | – | – | – | 14.3% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
8 Sep · Approval Of Additional Products From Drugs Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies Limited
Gennex Laboratories share price by year
Each calendar year to 2025.Gennex Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 14.30 | −12.4% | 18.71 | 11.18 |
| 2024 | 16.33 | −2.9% | 27.87 | 13.58 |
| 2023 | 16.81 | +163.1% | 17.25 | 4.99 |
| 2022 | 6.39 | −42.2% | 12.48 | 6.01 |
| 2021 | 11.05 | +135.6% | 12.19 | 3.80 |
| 2020 | 4.69 | +79.7% | 5.78 | 1.41 |
| 2019 | 2.61 | −31.5% | 4.51 | 2.39 |
| 2018 | 3.81 | −33.5% | 6.25 | 3.05 |
| 2017 | 5.73 | −7.1% | 7.57 | 3.33 |
| 2016 | 6.17 | −36.5% | 13.77 | 6.05 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on BSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 8.95 | 8.99 | 8.50 | 8.70 | 8.64 | 2,30,459 |
| 22 Oct 2026 | 8.99 | 8.99 | 8.76 | 8.85 | 8.89 | 1,40,496 |
| 21 Oct 2026 | 9.10 | 9.20 | 8.60 | 8.90 | 8.85 | 3,62,954 |
| 19 Oct 2026 | 9.20 | 9.20 | 8.80 | 8.97 | 8.90 | 3,35,227 |
| 16 Oct 2026 | 9.30 | 9.47 | 8.90 | 9.02 | 9.03 | 8,42,214 |
| 15 Oct 2026 | 9.21 | 9.43 | 9.21 | 9.28 | 9.33 | 2,37,232 |
| 14 Oct 2026 | 9.25 | 9.55 | 9.25 | 9.43 | 9.44 | 2,50,105 |
| 13 Oct 2026 | 9.59 | 9.83 | 8.27 | 9.21 | 8.99 | 8,29,282 |
| 12 Oct 2026 | 9.65 | 9.89 | 9.51 | 9.58 | 9.71 | 1,60,131 |
| 9 Oct 2026 | 9.72 | 9.99 | 9.51 | 9.61 | 9.70 | 2,83,302 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 21 Jul 2022 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 14 Dec 2009 | Split | 0.1000 | Each share became 10. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Gennex Laboratories Ltd
- BSE code
- 531739
- ISIN
- INE509C01026
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- May 1996
- Face value
- ₹1
- CIN
- L24230TG1990PLC011168
- Corporate identity number, the registrar of companies' code for it